Citi Defending Apogee Therapeutics Inc (APGE): 'we are buyers on weakness'
Tweet Send to a Friend
Citi analyst Geoff Meacham reiterated a Buy rating and $95.00 price target on Apogee Therapeutics Inc (NASDAQ: APGE).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
